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Carcinoembryonic antigen-related cell adhesion molecule
1 (CEACAM1) regulates insulin sensitivity by promoting
hepatic insulin clearance. Liver-speciﬁc inactivation or
global null-mutation of Ceacam1 impairs hepatic insulin
extraction to cause chronic hyperinsulinemia, resulting
in insulin resistance and visceral obesity. In this study
we investigated whether diet-induced insulin resistance
implicates changes in hepatic CEACAM1. We report that
feeding C57/BL6J mice a high-fat diet reduced hepatic
CEACAM1 levels by >50% beginning at 21 days, causing
hyperinsulinemia, insulin resistance, and elevation in he-
patic triacylglycerol content. Conversely, liver-speciﬁc in-
ducible CEACAM1 expression prevented hyperinsulinemia
and markedly limited insulin resistance and hepatic lipid
accumulation that were induced by prolonged high-fat
intake. This was partly mediated by increased hepatic
b-fatty acid oxidation and energy expenditure. The data
demonstrate that the high-fat diet reduced hepatic
CEACAM1 expression and that overexpressing CEACAM1
in liver curtailed diet-induced metabolic abnormalities by
protecting hepatic insulin clearance.
Insulin resistance, the hallmark of metabolic diseases, is
commonly heralded by hyperinsulinemia. The cause-and-
effect relationship between chronic hyperinsulinemia and
reduced insulin response remains somewhat elusive but
has received renewed interest (1–3). Peripheral insulin
resistance induces compensatory insulin secretion, result-
ing in hyperinsulinemia. Reciprocally, hyperinsulinemia
causes insulin resistance via mechanisms including down-
regulating insulin receptors (4) and promoting hepatic de
novo lipogenesis, in part, by activating the sterol regulatory
element–binding protein (SREBP1c), a master regulator
transcription factor that induces lipogenic genes expression
(5). This elevates hepatic lipid production and redistribu-
tion to white adipose tissue (WAT) for storage, causing
visceral obesity. With persistent nutritional burden, insulin
resistance develops in WAT, manifested by lipolysis and
progression of a proinﬂammatory state (6).
Released fatty acids from WAT could redistribute to
other tissues, in particular the liver (the portal hypothesis),
causing lipotoxicity and insulin resistance (7,8). Increased
fatty acid supply causes insulin resistance (9) by impairing
insulin clearance through protein kinase C-d–mediated
mechanisms (10) and contributing to lipid accumulation
in hepatocytes, which, in turn, induces a local inﬂamma-
tory response (11). In addition, the rise in WAT-derived
adipokines modulates the intrahepatic proinﬂammatory
milieu to contribute to pathways amplifying insulin resis-
tance (6). Thus, systemic inﬂammation in diet-induced
obesity occurs late in the progression of the disease (12) by
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comparison with hyperinsulinemia and insulin resistance
(13,14).
In addition to increased insulin secretion, impaired
insulin clearance contributes to mounting hyperinsulinemia
in obese humans (15,16) and dogs (17) and in subjects at
high risk for metabolic syndrome (18) and type 2 diabetes
(19). Furthermore, studies demonstrate that an ;10%
weight loss improves insulin clearance (20) but not secre-
tion, which requires a more signiﬁcant weight loss (16).
Consistent with a role for the carcinoembryonic antigen-
related cell adhesion molecule 1 (CEACAM1) in promoting
receptor-mediated insulin uptake and degradation in hepa-
tocytes (21), hepatic insulin clearance is impaired in mice
with liver-speciﬁc CEACAM1 inactivation (L-SACC1) or
global mutation (Cc12/2) (22–24). This is followed by
hyperinsulinemia and insulin resistance (22–24) in addi-
tion to elevated lipid production in liver and accumulation
in WAT (25). Hyperinsulinemia in Cc12/2 mice occurs
without altered insulin secretion despite loss of CEACAM1
from b-cells (23). Thus, studies on CEACAM1 provide
convincing evidence that hyperinsulinemia resulting from
impaired insulin clearance causes insulin resistance and vis-
ceral obesity.
Moreover, hepatic CEACAM1 levels are markedly
reduced in humans with insulin resistance, obesity, and
fatty liver disease (26). Because dietary factors play an
important role in the development of insulin resistance,
we investigated whether administration of a high-fat (HF)
diet represses CEACAM1-dependent insulin clearance path-
ways in C57/BL6J mice (BL6) and whether this plays a role
in diet-induced insulin resistance.
RESEARCH DESIGN AND METHODS
Mice Generation
Transgenic mice with liver-speciﬁc overexpression of rat
CEACAM1 (L-CC1) were generated using human apolipo-
protein A1 (APOA1) promoter/enhancer element (27)
(Fig. 1A), as described (22). The “minigene” construct
was obtained by subcloning 519 nucleotides of proximal
APOA1 promoter 59 of a Ceacam1 rat minigene containing
intron1. This was subcloned into plasmid cytomegalovirus
(pCMV)-3Tag-3A plasmid at Not1 site to encode a FLAG-
tagged rat CEACAM1 protein. The 39-FLAG-tagged APOA1/
wild-type (WT) rat Ceacam1 minigene was excised and
injected in the pronuclei of single-cell fertilized mouse
embryos from SJLXC57Bl/6J matings (Yale Transgenic
Facility). PCR analysis of tail genomic DNA was used to
identify 11 F0 founders. Two lines were identiﬁed and
backcrossed six times on the BL6 background (The Jackson
Laboratory).
Mice were kept in a 12-h dark/light cycle. Male mice (2
months old) were fed ad libitum a standard regular diet
(RD) deriving 12% calories from fat, 66% from carbohydrate,
and 22% calories from protein or a high-calorie HF diet
deriving 45% of calories from fat, 35% from carbohydrate,
and 20% from protein (Catalog #D12451, Research Diets).
Fatty acid composition in the HF diet was 36% saturated
fatty acids, 45% monounsaturated fatty acids, and 19%
polyunsaturated fatty acids. The Institutional Animal Care
and Utilization Committee approved all procedures.
Metabolic Parameters
Retro-orbital venous blood was drawn at 1100 h from
mice fasted overnight to assess plasma insulin levels (Linco
Figure 1—Generation of L-CC1 transgenic mice with liver-speciﬁc
overexpression of CEACAM1. A: L-CC1 transgenic mice over-
expressing FLAG-tagged WT rat CEACAM1 in the liver were gen-
erated using the human APOA1 promoter/enhancer element. The
“minigene” construct was obtained by subcloning 519 nucleotides
of proximal APOA1 promoter 59 of a Ceacam1 rat minigene containing
intron 1, subcloned into plasmid cytomegalovirus (pCMV)-3Tag-3A
plasmid at Not1 site to encode a FLAG-tagged rat CEACAM1 protein.
B: Liver (Liv) and intestinal (Int) lysates were analyzed by immunoblot-
ting (Ib) with polyclonal antibodies against rat CEACAM1 (a-rCC1) and
FLAG (a-FLAG), followed by reprobing (reIb) with a-actin antibody for
protein normalization. Gels represent more than two experiments on
more than three mice per genotype. C: Western analysis of liver pro-
teins from WT mice fed the RD or HF diet for 30 days with a-APOA1
and albumin polyclonal antibodies (n = 3 per group). Data indicate
induced expression of APOA1, but not albumin, by the HF diet.
Gels represent more than two experiments on two different sets of
mice. Di: WT and L-CC1 mice were fed the HF or RD for 4 months
before liver lysates were analyzed by Western blotting using antibod-
ies against rat (rCC1) and mouse (mCC1) proteins, followed by a-actin
for normalization. Dii: Liver lysates were also analyzed by quantitative
RT-PCR to determine mRNA of Ceacam1 using primers common to
both rat and mouse genes (total Ceacam1) and normalized to GAPDH.
*P< 0.05 HF vs. RD per genotype. †P< 0.05 L-CC1 vs. WT per same
feeding group.
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Research), nonesteriﬁed fatty acids (NEFA C; Wako),
triacylglycerol (Pointe Scientiﬁc), and ﬁbroblast growth
factor 21 (FGF21; BioVendor) (23).
Body Composition
Whole-body composition was assessed by 1H-MRS (Echo
Medical Systems).
Hyperinsulinemic-Euglycemic Clamp Analysis
A 2-h hyperinsulinemic-euglycemic clamp was performed
in awake overnight-fasted mice (n = 10 per feeding group per
genotype) with primed and continuous infusion of human
regular insulin (Humulin) at a rate of 2.5 mU $ kg21 $ min21
(23). Glucose metabolism was estimated with a continuous
infusion of 0.05 mCi/min of [3-3H]glucose (PerkinElmer and
Analytical Sciences) before and 0.1 mCi/min throughout
the clamp. Insulin levels were measured using the Mouse
Ultrasensitive Insulin ELISA Kit from Alpco.
Glucose and Insulin Tolerance Tests
Awake overnight-fasted mice were injected intraperitoneally
(i.p.) with 1.5 g/kg body weight (BW) dextrose solution
before glucose was measured in tail blood. For insulin
tolerance, mice were fasted for 6 h, injected with human
regular insulin (Novo Nordisk; 0.75 units/kg BW i.p.), and
their glucose was measured.
In Vivo Insulin Clearance
Human [125I]insulin (1640Bq/mouse; PerkinElmer) was
injected in overnight-fasted anesthetized mice via tail
vein, and retro-orbital blood was immediately drawn every
10 s for 2 min (22,24). Blood radioactivity was counted
(gamma-counter), and the insulin clearance rate was
calculated as the percentage of 10-s postintravenous
radioactivity.
Glucose Uptake in Muscle
Glucose uptake in response to insulin (1,200 pmol/L) was
measured in soleus muscle from hind limbs of fasted mice
in the presence of 2-deoxy-D-[l,2-3H]glucose (DG, 1 mmol/L)
and [U-14C]mannitol (39 mmol/L) (22). Muscle was frozen
in liquid nitrogen, and the intracellular 2-DG level was mea-
sured in nmol $ g wet muscle21 $ min21.
Ex Vivo Palmitate Oxidation
Soleus and gastrocnemius muscle of overnight-fasted
mice were assayed as described (28) with modiﬁcations
(29). Muscle was homogenized in 10 mmol/L Tris (pH 7.2),
300 mmol/L sucrose, and 2 mmol/L EDTA, injected by
syringe into a sealed beaker to be incubated at 30°C for
45 min in the presence of 0.2 mmol/L of [1-14C]palmitate
(0.5 mCi/mL) and 2 mmol/L ATP in incubation buffer
(100 mmol/L sucrose, 10 mmol/L Tris-HCl, 5 mmol/L po-
tassium phosphate, 80 mmol/L KCl, 1 mmol/L MgCl2,
2 mmol/L L-carnitine, 0.1 mmol/L malic acid, 0.05 mmol/L
CoA, 1 mmol/L dithiothreitol, 0.2 mmol/L EDTA, and 0.5%
BSA, pH 7.4). The reaction was terminated with glacial
acetic acid, and trapped CO2 radioactivity was measured
by liquid scintillation in CytoScint (MP Biomedicals).
Primary Hepatocytes
Hepatocytes were isolated by perfusing liver (1 mL/min)
with collagenase type II solution (1 mg/mL) (Worthington)
(22). Cells were dispensed in Williams E complete media
(10 mmol/L lactate, 10 nmol/L dexamethasone, 100 nmol/L
insulin, 10% FBS, and 1% penicillin-streptomycin), counted,
and plated onto 12-well cell culture plates at 2.5 3 105/well
density and incubated at 37°C for 48 h. Cells from HF-
fed mice were supplemented with 0.1 mmol/L fatty acid
(0.035 mmol/L palmitic acid, 0.045 mmol/L oleic acid,
and 0.02 mmol/L linoleic acid, and 2 mmol/L insulin-free
BSA [Sigma-Aldrich A7888] at a 1:5 ratio). Medium was
changed 24 h after plating.
Primary Proximal Tubule Cells
Kidney cortices were ﬁnely cut, reconstituted in 1 mL
Solution 1 (DMEM-F12, 1 mmol/L heptanoate acid and
4 mmol/L glycine, pH 7.4), digested three times (shaking
at 37°C in 100% oxygen for 12 min) in 10 mL collagenase
solution (1 mg/mL collagenase type II [Worthington],
1 mg/mL insulin-free BSA, and 0.1 mg/mL DNase I
[Sigma-Aldrich]), and allowed to settle down into a sterile
pipette (30). Supernatant was centrifuged at 1,000 rpm at
4°C for 5 min, and the cell pellet was reconstituted in
Percoll Solution (colloidal silica particles of 15–30 nm diam-
eter, 23% w/w in water, coated with polyvinyl-pyrrolidone
[Sigma-Aldrich]), and ultracentrifuged (17,000 rpm at 40°C
for 30 min). Cells between the third and fourth layer at
;1.0–1.3 g/mL Percoll density were collected, washed twice
in 50 mL Solution 1 (1,000 rpm, 4°C, 5 min), and incubated
in six-well plates for 3–5 days in DMEM/F-12 culture me-
dium (Sigma-Aldrich), containing 1% penicillin-streptomycin,
60 nmol/L sodium selenite, 1.1 mg/mL sodium bicar-
bonate, 5 mg/mL human apo-transferrin, 2 mmol/L
glutamine, 50 nmol/L dexamethasone, 5 pmol/L 3,5,39-
triiodothyronine, 25 ng/mL prostaglandin E1, 50 nmol/L
hydrocortisone, 10 ng/mL epidermal growth factor, 5 mg/mL
insulin, 3.1 g/L D-glucose, 2% (vol/vol) FBS, and 20 mmol/L
HEPES, pH 7.4 (Invitrogen and Sigma-Aldrich). The fatty acid
mixture (above) containing 10 mmol/L lactate was added to
cells from HF-fed mice. Medium was changed 24 h after
plating. Cells were kept in the culture medium for 48–72 h.
Ligand Binding and Internalization in Cells
[125I]insulin (Human [125I]-insulin, PerkinElmer) (30,000
cpm) was allowed to bind to isolated cells at 4°C for 5 h in
cold Krebs-Ringer phosphate buffer (100 mmol/L HEPES,
pH 7.4; 120 mmol/L NaCl, 1.2 mmol/L MgSO4, 1 mmol/L
EDTA, 15 mmol/L CH3COONa, 10 mmol/L glucose, and
1% BSA). Unbound insulin was removed in cold 1 3 PBS,
and cells were incubated in 1 mL Krebs-Ringer phosphate
buffer at 37°C for 0–90 min, washed, and incubated with
900 mL acidic PBS (pH 3.5) for 10 min on ice to remove
surface-bound insulin. Hepatocytes were washed and
lysed with 0.4N NaOH to account for cell-associated inter-
nalized insulin. The acid wash was counted as surface-bound
and NaOH-solubilized cells as internalized cell-associated
ligand. Internalized insulin was calculated as percent
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cell-associated per speciﬁcally bound ligand (the sum of
surface-bound plus cell-associated ligand).
b-Cell Area and Immunohistochemistry
Pancreas was weighed, ﬁxed in Bouin solution, sectioned,
and stained (23). Antibodies were guinea pig anti-human
insulin (Linco Research) and aminomethylcourmain -conjugated
donkey anti-guinea pig antibody (Jackson ImmunoResearch)
for insulin and anti-mouse glucagon monoclonal antibody
(Sigma-Aldrich) and Texas red-conjugated donkey anti-mouse
antibody (Jackson ImmunoResearch) for glucagon. Areas of
b-cells and a-cells were calculated by morphometric analysis
using ImageJ software (National Institutes of Health;
http://rsb.info.nih.gov/ij/) and divided by total pancreas area.
Western Analysis
Proteins were analyzed by 7% SDS-PAGE and immuno-
probing with polyclonal antibodies against phospho-Akt
(Ser473, Cell Signaling Technology), followed by a-Akt
antibody. Also used were polyclonal antibodies against
mouse CEACAM1 (25), rat CEACAM1 (a-rCC1) (23), and
fatty acid synthase (a-Fasn) (25). For normalization, mono-
clonal antibodies against actin, GAPDH, and tubulin
(Sigma-Aldrich or Santa Cruz Biotechnology) were used.
Blots were incubated with horseradish peroxidase-conjugated
anti-goat IgG (Santa Cruz Biotechnology), anti-mouse or
anti-rabbit IgG (Amersham) antibodies, subjected to en-
hanced chemiluminescence (Amersham), and quantiﬁed
by densitometry (ImageJ software).
Northern Analysis
mRNA was puriﬁed using TRIzol (Invitrogen), followed
by the MicroPoly(A) Pure kit (Ambion) and analysis by
probing with Ceacam1 cDNAs, using the Random Primed
DNA Labeling Kit (Roche), before reprobing and normal-
izing to b-actin.
Semiquantitative Real-Time RT-PCR
Total RNA was isolated with PerfectPure RNA Tissue Kit
(5 Prime) following the manufacturer’s protocol. cDNA was
synthesized by ImProm-II Reverse Transcription System
(Promega), using 1 mg total RNA and oligo dT primers (Sup-
plementary Table 1). cDNA was evaluated with quanti-
tative RT-PCR (StepOnePlus, Applied Biosystems). mRNA
was normalized to GAPDH or 18S.
Statistical Analysis
Data were analyzed with SPSS software by two-way
ANOVA or the two-tailed Student t test with GraphPad
Prism 4 software. P , 0.05 was statistically signiﬁcant.
RESULTS
HF Diet Causes Insulin Resistance
HF feeding for 9–30 days progressively increased visceral
obesity and, subsequently, lipolysis and plasma NEFA in
WT mice (Table 1). In parallel, it caused insulin resistance,
manifested by fed hyperglycemia (Table 1) and glucose
and insulin intolerance beginning at 21 days (Fig. 2A,
i and ii, respectively). Given that overnight fasting re-
verses diet-induced glucose intolerance, particularly in
liver (31), it is possible that hepatic insulin resistance
may have occurred earlier. Nonetheless, Western analysis
revealed that an insulin surge after 7 h of refeeding (25)
(358. 6 47.8 vs. 39.1 6 3.16 pmol/L at fasting; P, 0.05)
induced Akt phosphorylation (by ;2- to 10-fold) in liver,
soleus muscle, and WAT of mice fed an RD (Supplemen-
tary Fig. 1A, i). In mice fed an HF diet for 28 days,
however, insulin release after refeeding (1,128. 6
70.53 vs. 38.72 6 1.408 pmol/L at fasting; P , 0.05)
induced Akt phosphorylation in muscle and WAT, but
not liver. Together, this shows altered insulin signaling
in liver by HF.
HF Diet Impairs Insulin Clearance and Causes
Hyperinsulinemia
HF feeding for 30 days caused hyperinsulinemia (Table 1)
that could result partly from the compensatory increase
in insulin secretion, as demonstrated by the more robust
acute-phase insulin release in response to the intraperitoneal
injection of glucose (data not shown).
Table 1—Effect of HF diet on plasma and tissue biochemistry in BL6 male mice
9 days 30 days
RD HF RD HF
Visceral fat/body weight (%) 1.2 6 0.1 1.9 6 0.1* 1.4 6 0.3 3.8 6 0.4*
Fasting plasma
NEFA (mEq/L) 0.5 6 0.1 0.7 6 0.1 0.5 6 0.1 1.0 6 0.1*
Insulin (pmol/L) 36.2 6 0.72 39.9 6 1.04 35.6 6 1.66 59.8 6 5.84*
C-peptide (pmol/L) 266. 6 34.0 277. 6 22.0 307. 6 53.2 351. 6 39.8
C-peptide–to–insulin molar ratio 8.0 6 0.2 7.0 6 0.1 9.0 6 0.1 5.1 6 0.0*
Hepatic triacylglycerol (mg/mg protein) 183. 6 23.8 312. 6 67.6 166. 6 21.1 688. 6 128.*
Blood glucose (mg/dL)
Fasting 100. 6 2.10 104. 6 5.60 96.5 6 5.90 111. 6 7.00
Fed 101. 6 5.31 108. 6 7.02 103. 6 4.41 136. 6 14.9*
Mice (4 months of age, n . 6 per feeding group) were fed RD or HF for 9 or 30 days. Values are expressed as mean 6 SEM. *P , 0.05
HF vs. RD per feeding period.
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Diet-induced hyperinsulinemia could also result from
impaired hepatic insulin clearance, as supported by a) the
signiﬁcant approximately twofold decrease in steady-state
C-peptide–to–insulin molar ratio by HF intake for 30, but
not 9 days (Table 1), and b) the higher amount of residual
125I-labeled plasma insulin within 90 s after an intravenous
injection in HF-fed relative to RD-fed WT mice as measured
by the area under the curve (AUC) of the decrease in plasma
insulin with postinjection time (Fig. 3A, accompanying
graph). That injected insulin is cleared less efﬁciently could
explain the sustained decrease in glucose levels in HF-treated
mice in some experiments (Fig. 2A, ii, right panel).
We then examined the effect of HF on CEACAM1 expres-
sion. Northern and Western analyses showed a decline in
CEACAM1 mRNA and protein levels by .50% after 21–28
days of HF feeding in the liver (Fig. 2B) and kidney (Fig. 2C),
the two main sites of insulin clearance.
Role of Hepatic CEACAM1 Overexpression in
Diet-Induced Insulin Resistance
Because CEACAM1 mediates insulin clearance, we then
investigated whether the observed decrease of CEACAM1
Figure 2—Effect of HF diet on insulin and glucose tolerance and
on CEACAM1 protein levels. A: BL6 mice (2 months old) were fed
an RD (■) or an HF diet (□) for 12–28 days before they were
challenged with an intraperitoneal injection of glucose (1.5 g/kg
BW) (i) or insulin (0.75 units/kg body weight) (ii) to assess blood
glucose levels at 0–180 min postinjection. *P < 0.05 HF vs. RD
(n > 6 per feeding group). B: Liver lysates were subjected to
Northern (i) and Western (ii) analyses and reprobing with b-actin
cDNA and a-actin antibody, respectively, for normalization (n > 6
mice per feeding group). Bands were scanned, and the density
was measured with arbitrary units (AU) and represented in the
right-hand graphs. The numbers above the gel denote different
mice. *P < 0.05 vs. RD. C: Kidney lysates from three mice per
feeding group were subjected to sequential Ib with a-mouse
CEACAM1 antibody, followed by reprobing (reIb) with a-actin
antibody for normalization.
Figure 3—Effect of HF diet on insulin clearance. A: Metabolic
clearance of 125I-insulin injected in the tail vein was measured
in 4-month-old mice (n = 8 mice per feeding group per genotype)
fed the HF diet (dashed lines) or the RD (solid lines) for 1 month.
Blood 125I-insulin was counted after 10–90 s postinjection. Values
are expressed as mean 6 SEM of percent of the amount of blood
insulin at 10 s. AUC of the decrease in plasma insulin with post-
injection time was calculated and is presented in the accompa-
nying bar graph. Bi: 125I-insulin internalization in primary hepatocytes
derived from mice fed an HF (dashed lines) or RD (solid lines) for 4
months was measured. After binding, 125I-insulin was allowed to
internalize at 37°C for 0–90 min (horizontal axis). Internalized li-
gand was plotted on the vertical axis as percent of the speciﬁcally
bound ligand. Values are expressed as mean 6 SD from triplicate
experiments performed on more than three mice per feeding
group per genotype. Bii: Western blot analysis of lysates of pri-
mary hepatocytes to analyze the amount of rat (rCC1) and mouse
(mCC1) CEACAM1 normalized to actin. Ci: Primary proximal tubule
cells were isolated from at least eight mice per feeding group per
genotype, mixed, and subjected to 125I-insulin internalization. The
experiment was repeated three times. Cii: Some aliquots of isolated
cells were lysed and analyzed by Western blot to assess CEACAM1
level normalized to actin. A representative gel of more than two
experiments is shown. A–C: Values are expressed as mean 6
SEM. *P < 0.05 HF vs. RD per genotype. †P < 0.05 L-CC1 vs.
WT per same feeding group.
2784 CEACAM1 in Diet-Induced Insulin Resistance Diabetes Volume 64, August 2015
in response to HF contributed mechanistically to hyper-
insulinemia-driven insulin resistance. To this end, we
generated transgenic mice (L-CC1) overexpressing FLAG-
tagged rat CEACAM1 in the liver, using a human APOA1
promoter (22) (Fig. 1A). Immunoblotting (Ib) with a-Flag
and a-rat CEACAM1 (a-rCC1) antibodies demonstrated
expression of the WT rat transgene in the liver (Fig. 1B,
Liv) but not intestine (Fig. 1B, Int), the other main site of
APOA1 production (32), as was the case for L-SACC1 mice
(22). Unlike endogenous mouse CEACAM1, which under-
went a .50% reduction (Fig. 1D, i; Ib: a-mCC1), trans-
genic rat CEACAM1 protein was protected (Ib: a-rCC1)
even after 4 months of HF intake. Quantitative RT-PCR
analysis using primers that bind to mouse and rat Ceacam1
showed that HF failed to lower total Ceacam1 mRNA levels
(Fig. 1D, ii), likely owing to APOA1 induction by the HF
diet (Fig. 1C).
As opposed to WT mice, HF did not signiﬁcantly alter
the AUC of plasma residual 125I-insulin 90 s after tail vein
injection in L-CC1 mice, keeping it at a comparable level
to that in RD-fed WT mice (Fig. 3A, accompanying graph).
Consistently, 125I-insulin internalization was markedly
lower in hepatocytes isolated from WT mice fed HF for
4 months, but not L-CC1 mice (Fig. 3B, i) in parallel to
preserved CEACAM1 protein levels in transgenic mice
(Fig. 3B, ii). As a control, we analyzed insulin internalization
in kidney cells, which express CEACAM1 and contribute
to a lower degree to insulin clearance (33). HF reduced
125I-insulin internalization in primary proximal tubule cells
from both mouse groups (Fig. 3C, i), consistent with re-
duction of their CEACAM1 protein levels (Fig. 3C, ii). In
parallel, HF did not alter plasma insulin levels in L-CC1
after 30 days (Supplementary Table 2) and only slightly
(by ;1.3-fold) induced it after 4 months, as opposed to
WT mice in which it elevated insulin levels by ;2- to
2.5-fold after 1–4 months (Tables 1 and 2). The data are
consistent with protected hepatic, but not renal insulin
clearance in L-CC1 mice, an event that limits HF-induced
hyperinsulinemia.
HF intake for 28 days did not alter Akt activation in
L-CC1 liver in response to the fourfold rise in insulin
upon refeeding (Supplementary Fig. 1A, ii), nor did it affect
glucose or insulin tolerance (Supplementary Fig. 1B). To
assess the effect of prolonged HF intake in vivo, a 2-h
hyperinsulinemic-euglycemic clamp was performed on mice
fed HF for 4 months (Fig. 4A). Basal glucose at the beginning
of the clamp (not shown) and basal hepatic glucose produc-
tion (Fig. 4A, i), a measure of rate of appearance at the
preclamp condition, were similar in both groups of mice
fed RD or HF. During the clamp, at comparable glucose
(Fig. 4A, ii) and insulin (Fig. 4A, iii) levels, HF reduced the
glucose infusion rate required to maintain euglycemia in
L-CC1 mice to a much lesser extent than in WTmice, leading
to an approximately twofold higher glucose infusion rate in
HF-fed transgenic mice (Fig. 4A, iv). Consistently, HF re-
duced the ability of insulin to suppress hepatic glucose pro-
duction (by ;45%) and whole-body glucose disposal in WT
but not L-CC1 mice (Fig. 4A, v and vi, respectively). More-
over, HF induced whole-body glycolysis in L-CC1 mice (Fig.
4A, vii), contributing to higher glucose turnover compared
with HF-fed WT mice. In contrast, glycogen synthesis was
comparable in WT and L-CC1 mice under both feeding con-
ditions (not shown). Contributing to higher glucose turnover
in HF-fed L-CC1 mice and a higher glucose infusion rate
during the hyperinsulinemic-euglycemic clamp was the rise
of glucose uptake in response to submaximal concentrations
of insulin (0.3 mU/mL) in the oxidative soleus muscle of
HF-fed transgenic mice (Fig. 4B). That systemic insulin sen-
sitivity is preserved is also supported by the limited induc-
tion of lipolysis (assessed by fasting plasma NEFA levels)
after 1–4 months of HF feeding in L-CC1 mice, by compar-
ison with WTmice, where HF-induced lipolysis was observed
(Table 2 and Supplementary Table 2). Taken together,
the data suggest that liver-speciﬁc CEACAM1 overexpres-
sion restricted the adverse effect of a sustained HF diet on
insulin action.
Consistent with the well-known increase in insulin
secretion to compensate for insulin resistance, HF feeding
Table 2—Effect of HF diet for 4 months on plasma and tissue biochemistry
WT L-CC1
RD HF RD HF
Body weight (g) 25. 6 1.0 35. 6 2.0* 25. 6 0.1 32. 6 1.0*
Total fat mass (g) 1.8 6 0.3 13. 6 1.1* 2.1 6 0.3 9.6 6 0.8*†
Total lean mass (g) 24.3 6 0.42 25.4 6 0.41 24.6 6 0.44 24.9 6 0.53
Fasting plasma
C-peptide–to–insulin molar ratio 12.1 6 0.68 8.62 6 0.31* 11.2 6 0.62 11.1 6 0.52†
Insulin (pmol/L) 68.1 6 3.54 153. 6 15.2* 60.4 6 4.25 87.6 6 6.72*†
NEFA (mEq/L) 0.60 6 0.02 0.86 6 0.04* 0.62 6 0.03 0.70 6 0.04†
Hepatic triacylglycerol (mg/mg protein) 131. 6 5.80 450. 6 15.0* 140. 6 8.30 160. 6 11.1†
Fed blood glucose (mg/dL) 133. 6 2.20 162. 6 3.45* 132. 6 4.10 142. 6 3.68†
Mice (n.10/feeding group/genotype) were fed an HF diet for 4 months starting at 2 months of age. Lean mass (g) and fat mass (g) were
determined using MRS. Values are expressed as mean6 SEM. *P, 0.05 HF vs. RD per genotype. †P, 0.05 L-CC1 vs. WT per feeding
group.
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for 4 months caused an increase in b-cell area of WT but
not L-CC1 mice, as assessed by immunohistochemical
analysis with a-insulin antibody (blue) (Fig. 4C). Immu-
nostaining with a-glucagon antibody (red) revealed fail-
ure of HF feeding to alter a-cell area in WT and L-CC1
mice (Fig. 4C, graph).
Role of Hepatic CEACAM1 Overexpression in Diet-
Mediated Alteration of Hepatic Lipid Metabolism
HF feeding for 30 days signiﬁcantly induced hepatic mRNA
levels of Srebp1c in WT (1.93 6 0.25 vs. 0.93 6 0.07; P ,
0.05), but not L-CC1 mice (1.23 6 0.10 vs. 0.90 6 0.15).
Consistently, the protein level of Fasn, a transcriptional tar-
get of Srebp1c, was induced by HF in WT, but not L-CC1
mice (Fig. 5A). This could contribute to mechanisms under-
lying increased triacylglycerol content in the liver of HF-fed
WT mice (Tables 1 and 2 and Supplementary Table 2).
Lower lipid accumulation in L-CC1 livers could relate
partly to elevated fatty acid b-oxidation under both feed-
ing conditions (Fig. 5B, i). The parallel higher levels of
plasma FGF21 in L-CC1 versus WT mice under both feeding
Figure 4—Insulin action in response to prolonged HF diet. A: Overnight-fasted, awake 6-month-old mice fed the RD or HF diet for 4 months
(n$ 8 per feeding group per genotype) were subjected to a 2-h hyperinsulinemic-euglycemic clamp. Values are expressed as mean6 SEM
in mg/dL for hepatic glucose production (HGP) levels (Ra, rate of appearance), in ng/mL for insulin, and in mg/min/kg for all other
measurements. Rd, rate of disposal. *P < 0.05 HF vs. RD per genotype. †P < 0.05 L-CC1 vs. WT per feeding group. All clamp (c) insulin
values were signiﬁcantly higher than basal (b) per the same mouse group regardless of the diet, but for simplicity, the symbol is not
shown. B: Uptake of 2-deoxyglucose (2-DG) in the absence (2) or presence (+) of insulin was measured in soleus muscle isolated from
mice fed an HF diet for 6 months. Values are expressed as mean 6 SEM. *P < 0.05 vs. no insulin. C: Pancreas sections from mice fed
an HF diet for 4 months were ﬁxed and immunostained with antibodies against insulin (blue) and glucagon (red). b-Cell and a-cell areas
were estimated by morphometric analysis of 30–40 islets from each mouse group. Values are expressed as mean 6 SEM in arbitrary
units and presented in the graph. Photomicrographs are shown at original magniﬁcation 320. *P < 0.05 HF diet vs. RD per genotype.
†P < 0.05 L-CC1 vs. WT per feeding group.
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conditions (Fig. 5B, ii) could explain this ﬁnding because it
reﬂects primarily hepatic FGF21 levels (34).
Histological evaluation of hematoxylin and eosin–
stained liver sections of mice fed HF for 4 months revealed
diffused fat inﬁltration with predominantly microvesicular
steatosis and a mix of macrosteatosis in livers from HF-fed
WT mice (Fig. 5C). In contrast, HF-fed L-CC1 mice showed
more fat-free parenchyma with small affected areas.
Moreover, HF-fed WT livers exhibited more inﬂammatory
foci than HF-fed L-CC1 (Fig. 5C), as supported by the 10-fold
induction by HF in WT versus 4-fold in L-CC1 (Fig. 5C, ii
graph). Consistently, HF caused a twofold increase in CD68
mRNA in WT but not L-CC1 (Supplementary Fig. 2). Because
CD68 is an antigen expressed in macrophages manifesting
phagocytosis (35), the data support a lower inﬂammatory
state in HF-fed L-CC1 than in WT mice.
Role of Hepatic CEACAM1 Overexpression in
Diet-Mediated Alteration of Energy Balance
Consistent with induction of brown adipogenesis by
FGF21 (36,37), mRNA levels of Ucp1, a key gene in brown
adipogenesis, were elevated in WAT and brown adipose
tissue (BAT) of L-CC1 but not WT after 4 months of HF
intake (Fig. 5D and E, respectively).
This prompted us to assess energy expenditure in these
mice. Daily food intake of L-CC1 was similar to that in WT
mice when fed RD or HF for 4 months (Fig. 6A). Indirect
calorimetry analysis over a 24-h period revealed compa-
rable energy expenditure (heat generation) (Fig. 6B), VO2
(Fig. 6B), VCO2 (Fig. 6C), and spontaneous locomotor
activity (Fig. 6D) in L-CC1 and WT mice under normal
feeding conditions. Owing to normal VO2 and VCO2 levels,
the respiratory exchange ratio was also normal in L-CC1
mice (0.899 6 0.004) versus WT (0.875 6 0.008). HF
feeding markedly reduced energy expenditure and VO2 in
WT but not in L-CC1 mice (Fig. 6B), in addition to causing
a slight reduction in VCO2 in L-CC1 mice (Fig. 6C). The
respiratory exchange ratio was reduced to a similar extent
in both groups of mice upon HF feeding (0.801 6 0.008 in
HF-fed L-CC1 and 0.7806 0.013 in HF-WTmice). Moreover,
HF caused a marked reduction in spontaneous locomotor
activity of WT but not L-CC1 mice (Fig. 6D). Preserved energy
expenditure and physical activity could contribute to lower
fat mass in HF-fed L-CC1 than in HF-fed WT mice (Table 2).
DISCUSSION
The notion that hyperinsulinemia causes insulin resis-
tance has gained traction from observations in clinical
studies (1–3) as well as from our studies on Ceacam1
mutant mice (22–24). Moreover, reduced insulin clear-
ance, which could cause hyperinsulinemia, has emerged
as a risk factor for metabolic syndrome (18) as well as
type 2 diabetes, in particular among Hispanics and African
Americans (19). Because hepatic CEACAM1 content is re-
duced in patients with obesity, insulin resistance, and fatty
liver disease (26), the current studies addressed the role of
altered CEACAM1-dependent insulin clearance in hyperin-
sulinemia and insulin resistance in response to HF, a global
health risk factor. We show that HF reduced hepatic
CEACAM1 levels by .50% within 21 days in WT mice.
Consistent with the phenotype of Cc12/2 mice (23), this
impaired insulin clearance and caused hyperinsulinemia,
hepatic insulin resistance, and features of fatty liver dis-
ease. Conversely, gain-of-function of hepatic CEACAM1
markedly reduced hyperinsulinemia, insulin resistance,
and hepatic fat accumulation in response to prolonged
HF intake. This is consistent with the notion that
Figure 5—Effect of prolonged HF diet on lipid metabolism in liver.
A: Liver lysates were subjected to Western analysis with a-Fasn,
followed by a-actin antibody for normalization. Gel represents two
mice per each feeding group. Experiments were repeated twice. B:
Hepatic FAO (i) and plasma FGF21 (ii ) levels were determined in
mice fed the RD or HF diet per mouse group (n > 6 per feeding
group per genotype). Experiments were repeated at least three
times. Values are expressed as mean 6 SEM. *P < 0.05 HF vs.
RD per genotype. †P < 0.05 L-CC1 vs. WT per feeding group. Ci:
Liver histology was assessed in hematoxylin and eosin stained
sections (n > 4 mice per feeding group per genotype). In WT, HF
feeding caused predominantly microvesicular lipid inﬁltration (arrow-
head) alternating with normal liver parenchyma. It also caused portal
mononuclear inﬂammatory cell foci (arrow) in WT but not in L-CC1
mice, in which neither lipid nor inﬂammatory inﬁltration was almost
absent. Representative images from three sections per mouse are
shown. Cii: Inﬂammatory islands from mice were counted in four
sections per mouse, scored on a scale of 0–3, and plotted. Values
are expressed as mean 6 SEM. *P < 0.05 HF vs. RD per genotype.
†P < 0.05 L-CC1 vs. WT per feeding group. WAT (D) and BAT (E)
were lysed and mRNA levels analyzed in duplicates (n > 5 mice per
feeding group per genotype). Values are expressed as mean 6 SEM.
*P < 0.05 HF vs. RD per genotype.
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hyperinsulinemia caused by impaired insulin clearance can
play a signiﬁcant role in diet-induced insulin resistance and
nonalcoholic fatty liver disease.
Our ﬁnding of a progressive increase in fat mass
beginning at ;9 days of HF intake, followed by hyper-
insulinemia and insulin resistance, agrees with previous
reports (12,38). Schwartz and colleagues (12) showed that
a 60% fat diet induced hyperinsulinemia in BL6 mice,
before insulin resistance developed in liver and skeletal
muscle (4–8 weeks) and subsequently in WAT (;14 weeks).
This provided evidence of hyperinsulinemia preceding al-
tered insulin signaling in peripheral insulin target tissues.
Given that inducible liver-speciﬁc expression of CEACAM1
protected against hyperinsulinemia and insulin resistance
in L-CC1 mice, we propose that the HF diet reduced hepatic
CEACAM1 and, subsequently, impaired insulin clearance to
alter insulin response in hepatocytes, followed by systemic
insulin resistance.
That reduced insulin clearance plays a key role in diet-
induced resistance agrees with previous reports in mice
(39), dogs (40), and humans (41,42). Using a two-step
hyperinsulinemic-euglycemic clamp, human studies (42)
implicated reduction in insulin clearance in the rapid emer-
gence of hepatic insulin resistance in young and healthy
South Asian men, but not in Caucasians, after 5 days of an
HF Western diet. This altered hepatic insulin clearance
occurred in the absence of other differences in the meta-
bolic and biochemical responses in skeletal muscle and
WAT among both groups (42).
Inducible CEACAM1 expression in the liver increased
fatty acid b-oxidation under both feeding conditions. This
is likely due, at least partly, to higher hepatic FGF21 pro-
duction and release (34,43). Of note, the HF diet induced
fatty acid oxidation (FAO) in the WT and L-CC1 mice
despite reducing FGF21 production relative to the RD.
This points to an additional mechanism mediating FAO,
likely mediated by direct ligand-dependent activation of
peroxisome proliferator–activated receptor-a by “new fat”
(44). The mechanism underlying the induction of FGF21
expression by CEACAM1 overexpression remains unknown,
but that both proteins are induced by retinoic acid is intrigu-
ing (45,46). Further studies are needed to examine whether
retinoic acid–related mechanisms mediate this correlation
between hepatic CEACAM1 and FGF21 expression.
Overexpressing CEACAM1 in liver curtailed the nega-
tive effect of HF on locomotor activity and energy ex-
penditure. Together with increased brown adipogenesis
(47), increased activity could elevate energy dissipation.
Given that CEACAM1 is not produced by adipose tissue, it
is likely that extra-adipocytic mechanisms caused by he-
patic CEACAM1 overexpression drove the increase in
brown adipogenesis. This includes elevation in FGF21 re-
lease (36,37), which could induce locomotor activity (48).
Although future studies are necessary to dissect the mech-
anisms involved in the regulation of physical activity and
browning of adipose tissues by hepatic CEACAM1 induc-
tion, the L-CC1 response to the HF diet uncovers a puta-
tive novel role for hepatic CEACAM1 in regulating energy
expenditure.
That reduction of CEACAM1-dependent mechanisms
is implicated in diet-induced altered insulin and lipid
metabolism is supported by our previous studies on rats
selectively bred for low aerobic capacity. We have pre-
viously shown that hepatic CEACAM1 is markedly re-
duced in these rats relative to those with high aerobic
capacity (49) and that caloric restriction, but not exercise,
reversed hyperinsulinemia and insulin resistance in par-
allel to restoring hepatic CEACAM1 levels (50). Caloric
restriction also reversed lipid accumulation and other fea-
tures associated with nonalcoholic fatty liver disease in
these rats with low aerobic capacity, including inﬂamma-
tion, oxidative stress, and ﬁbrosis (50).
In summary, inducible CEACAM1 expression in liver
restricted diet-induced insulin resistance by preserving
insulin clearance and inducing hepatic b-oxidation and
Figure 6—Indirect calorimetry analysis. WT (left) and L-CC1 mice
(right) were fed RD (black or green) or HF diet (blue or red) for 4
months before being individually caged (n = 4 per feeding group per
genotype), given free access to food, and subjected to indirect
calorimetry analysis in a 24-h period for 5 days to measure daily
food intake (A), heat production (energy expenditure [EE]) (kcal/h/kg
lean mass) and VO2 consumption (mg/h/kg lean mass) (B), VCO2
production (mg/h/kg lean mass) (C), and spontaneous locomotor
activity (counts/day) (D). Values are expressed as mean 6 SEM of
each time interval in the last 3 days. *P < 0.05 HF-fed vs. RD-fed
per mouse group.
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energy dissipation. This provides a proof of principle that
induction of CEACAM1 could curb the adverse metabolic
effect of a HF diet.
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